This webinar covers widely used mouse models for familial Alzheimer's Disease (AD), the development of next-generation models through the MODEL-AD consortium, including late-onset Alzheimer's disease (LOAD) models, and guidance on selecting the AD models that will best suit your preclinical research.
This webinar discusses the shift toward antibody therapeutics as a more precise and targeted alternative to traditional therapies, highlighting their ability to selectively bind antigens and engage the immune system while minimizing toxicity. It covers key biological fundamentals, including the lymphatic system and B cell function, as well as antibody mechanisms such as neutralization and immune activation. Additionally, it outlines the therapeutic antibody discovery process and compares a variety of platforms like phage display, hybridoma, and transgenic mouse models.
[email protected]
1.800.422.6423 (US)
1.207.288.5845 (International)
Our technical scientists have curated lists of commonly asked questions. Check here for any question you have about your model, study, or procedure.
Find Your Answer +